HC Wainwright Increases LENZ Therapeutics (NASDAQ:LENZ) Price Target to $48.00

Key Points

• HC Wainwright raised its target price for LENZ Therapeutics stock from $38.00 to $48.00, indicating a potential upside of 51.80% from the current price.
• Piper Sandler has also initiated coverage on LENZ with an "overweight" rating and a price target of $51.00, reflecting strong analyst support for the stock.
• The company reported earnings of ($0.53) per share, exceeding analysts' expectations, while currently holding a market capitalization of approximately $890.10 million.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) had its target price upped by equities research analysts at HC Wainwright from $38.00 to $48.00 in a report released on Monday, July 28th, Marketbeat Ratings reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective indicates a potential upside of 58.20% from the company's current price. HC Wainwright also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($2.83) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $1.06 EPS and FY2029 earnings at $2.18 EPS.

Separately, Piper Sandler began coverage on LENZ Therapeutics in a research note on Monday, April 14th. They issued an "overweight" rating and a $51.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, LENZ Therapeutics has a consensus rating of "Buy" and an average price target of $49.60.

LENZ Therapeutics Price Performance

Shares of NASDAQ LENZ traded down $0.14 during mid-day trading on Monday, hitting $30.34. The company had a trading volume of 123,759 shares, compared to its average volume of 251,498. The company has a market capitalization of $865.33 million, a PE ratio of -16.03 and a beta of 0.42. LENZ Therapeutics has a 1-year low of $16.53 and a 1-year high of $38.93. The business's 50-day simple moving average is $31.07 and its 200 day simple moving average is $27.08.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.05. The company had revenue of $5.00 million during the quarter, compared to analyst estimates of $5.00 million. On average, analysts expect that LENZ Therapeutics will post -2.18 EPS for the current year.

Hedge Funds Weigh In On LENZ Therapeutics

Several hedge funds have recently made changes to their positions in LENZ. Paradigm Biocapital Advisors LP purchased a new position in shares of LENZ Therapeutics during the fourth quarter worth about $22,243,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of LENZ Therapeutics during the first quarter worth about $13,825,000. Price T Rowe Associates Inc. MD grew its holdings in shares of LENZ Therapeutics by 83.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company's stock worth $23,760,000 after buying an additional 374,326 shares during the last quarter. Granahan Investment Management LLC grew its holdings in shares of LENZ Therapeutics by 239.8% during the first quarter. Granahan Investment Management LLC now owns 176,166 shares of the company's stock worth $4,529,000 after buying an additional 124,324 shares during the last quarter. Finally, Scoggin Management LP purchased a new position in shares of LENZ Therapeutics during the first quarter worth about $2,571,000. Hedge funds and other institutional investors own 54.32% of the company's stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.